数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Robert Spiegel Director 69 未披露 未持股 2019-12-31
Spiro Rombotis President and Chief Executive Officer and Director 61 73.20万美元 未持股 2019-12-31
Paul McBarron Executive Vice President-Finance, Chief Financial Officer, Chief Operating Officer and Secretary,Director 59 35.65万美元 未持股 2019-12-31
John Banham Director 79 6.20万美元 未持股 2019-12-31
David U’Prichard Chairman of the Board of Director and Director 71 未披露 未持股 2019-12-31
Lloyd Sems Director 48 5.00万美元 未持股 2019-12-31
Gregory T. Hradsky Director 59 5.00万美元 未持股 2019-12-31
Samuel L. Barker Director 77 5.75万美元 未持股 2019-12-31
Christopher S. Henney Vice Chairman and Director 79 7.80万美元 未持股 2019-12-31
David U'Prichard Chairman of the Board of Director and Director 71 9.00万美元 未持股 2019-12-31

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Spiro Rombotis President and Chief Executive Officer and Director 61 73.20万美元 未持股 2019-12-31
Paul McBarron Executive Vice President-Finance, Chief Financial Officer, Chief Operating Officer and Secretary,Director 59 35.65万美元 未持股 2019-12-31
Judy Chiao Vice President, Clinical Development and Regulatory Affairs 60 48.48万美元 未持股 2019-12-31

董事简历

中英对照 |  中文 |  英文
Robert Spiegel

Robert Spiegel自2013年8月起在公司董事会工作。他自2012年起成为Weill Cornell Medical College的副教授,也是Warburg Pincus有限责任公司(Warburg Pincus, LLC)的咨询师。他也在PTC Therapeutics股份有限公司(PTC Therapeutics, Inc. NASDAQ: PTCT)担任医疗总监。在加入董事会之前,Spiegel博士在Schering-Plough公司(Schering-Plough Corporation)工作了超过25年,参与到临床开发(在2009年从Schering-Plough Research Institute的医疗总监和高级副总裁退休之前)。Spiegel博士担任Geron 公司(Geron Corporation (NASDAQ: GERN),一家生物技术肿瘤公司)的董事会成员在薪酬委员会和Avior Computing 公司(Avior Computing Corporation,一家治理风险和合规处理技术公司)工作。他先前是Talon Therapeutics股份有限公司(Talon Therapeutics, Inc.,前身是Hana Biosciences股份有限公司(Hana Biosciences, Inc.,一家生物制药肿瘤公司)董事,他也在审计委员会和Clavis Pharma ASA(一家制药公司,总部在挪威奥斯陆(Oslo, Norway))工作。Spiegel博士拥有耶鲁大学(Yale University)学士学位和宾夕法尼亚大学(University of Pennsylvania)硕士学位。在通过内科医学的住院医师实习后,他得到了国立癌症研究所(National Cancer Institute)的医学肿瘤奖学金,还有在国立癌症研究所(National Cancer Institute)和纽约大学癌症中心(New York University Cancer Center)的学术岗位任职。


Robert Spiegel has served as a member of our board of directors since December 2017. Since 2012 Dr. Spiegel has served as an Associate Professor at the Weill Cornell Medical School. In addition, Dr. Spiegel has served as a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund since 2010 and 2016 respectively. Prior to these positions, Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company, from March 2011 to April 2016. Prior to his time at PTC Therapeutics, Dr. Spiegel held various management positions at Schering-Plough Corporation, a global healthcare company, including as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation from 1998 to 2009. Dr. Spiegel is currently a member of the board of directors of Geron Corporation and Cyclacel Pharmaceuticals, Inc., biopharmaceutical company, since 2010 and 2018 respectively. Dr. Spiegel has previously served as a member of the board of directors for Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, Edge Therapeutics, Inc., a biotechnology company, Avior Computing Corporation, a privately-held governance risk and compliance process technology company, Talon Therapeutics, Inc., a biopharmaceutical company, Capstone Therapeutics Corp., a biotechnology company, the Cancer Institute of New Jersey and Cancer Care New Jersey. Dr. Spiegel received a B.A. in 1971 from Yale University and an M.D. from the University of Pennsylvania in 1975. Following his residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute.
Robert Spiegel自2013年8月起在公司董事会工作。他自2012年起成为Weill Cornell Medical College的副教授,也是Warburg Pincus有限责任公司(Warburg Pincus, LLC)的咨询师。他也在PTC Therapeutics股份有限公司(PTC Therapeutics, Inc. NASDAQ: PTCT)担任医疗总监。在加入董事会之前,Spiegel博士在Schering-Plough公司(Schering-Plough Corporation)工作了超过25年,参与到临床开发(在2009年从Schering-Plough Research Institute的医疗总监和高级副总裁退休之前)。Spiegel博士担任Geron 公司(Geron Corporation (NASDAQ: GERN),一家生物技术肿瘤公司)的董事会成员在薪酬委员会和Avior Computing 公司(Avior Computing Corporation,一家治理风险和合规处理技术公司)工作。他先前是Talon Therapeutics股份有限公司(Talon Therapeutics, Inc.,前身是Hana Biosciences股份有限公司(Hana Biosciences, Inc.,一家生物制药肿瘤公司)董事,他也在审计委员会和Clavis Pharma ASA(一家制药公司,总部在挪威奥斯陆(Oslo, Norway))工作。Spiegel博士拥有耶鲁大学(Yale University)学士学位和宾夕法尼亚大学(University of Pennsylvania)硕士学位。在通过内科医学的住院医师实习后,他得到了国立癌症研究所(National Cancer Institute)的医学肿瘤奖学金,还有在国立癌症研究所(National Cancer Institute)和纽约大学癌症中心(New York University Cancer Center)的学术岗位任职。
Robert Spiegel has served as a member of our board of directors since December 2017. Since 2012 Dr. Spiegel has served as an Associate Professor at the Weill Cornell Medical School. In addition, Dr. Spiegel has served as a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund since 2010 and 2016 respectively. Prior to these positions, Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company, from March 2011 to April 2016. Prior to his time at PTC Therapeutics, Dr. Spiegel held various management positions at Schering-Plough Corporation, a global healthcare company, including as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation from 1998 to 2009. Dr. Spiegel is currently a member of the board of directors of Geron Corporation and Cyclacel Pharmaceuticals, Inc., biopharmaceutical company, since 2010 and 2018 respectively. Dr. Spiegel has previously served as a member of the board of directors for Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, Edge Therapeutics, Inc., a biotechnology company, Avior Computing Corporation, a privately-held governance risk and compliance process technology company, Talon Therapeutics, Inc., a biopharmaceutical company, Capstone Therapeutics Corp., a biotechnology company, the Cancer Institute of New Jersey and Cancer Care New Jersey. Dr. Spiegel received a B.A. in 1971 from Yale University and an M.D. from the University of Pennsylvania in 1975. Following his residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute.
Spiro Rombotis

Spiro Rombotis,1997年加入Cyclacel,担任第一首席执行官,有着超过30年的制药与生物技术公司工作经验。之前,他曾在Liposome Company担任国际运营与业务开发副总裁、欧洲区总经理、日本合资企业总监。他还曾担任施贵宝的中欧与东欧区制药副总裁、国际营销总监。他曾是Centocor欧洲营销与销售总监、企业发展部总监,也是该公司最早的雇员之一;也曾在诺华公司从事业务开发的工作。他获得了Williams College的学士学位、工商管理硕士学位,并在Kellogg Graduate School of Management以优异成绩获得了医院管理硕士学位,他现任该校生物技术咨询委员会成员。他也是新泽西的生物技术行业贸易集团BioNJ的董事。


Spiro Rombotis has served as a director of the Company since March 2006. He joined Cyclacel as its first Chief Executive Officer in 1997. With over 34 years of experience at three publicly-held biotechs and two pharmas, he participated in several drug programs that reached the market, mainly in inflammation and hematology/oncology. Previously a Vice President and Managing Director, Europe at Liposome subsequently acquired by Elan and a Vice President at Bristol-Myers Squibb, he began his career in the early '80s after training at Novartis as one of the first employees of Centocor a pioneering biopharmaceutical company subsequently acquired by Johnson & Johnson. He holds a BA from Williams College and an MBA and Master's degree in Hospital & Health Services Management with honors from the Kellogg Graduate School of Management at Northwestern University. He also serves on the Board of Trustees of BioNJ, the biotechnology industry trade group in New Jersey.
Spiro Rombotis,1997年加入Cyclacel,担任第一首席执行官,有着超过30年的制药与生物技术公司工作经验。之前,他曾在Liposome Company担任国际运营与业务开发副总裁、欧洲区总经理、日本合资企业总监。他还曾担任施贵宝的中欧与东欧区制药副总裁、国际营销总监。他曾是Centocor欧洲营销与销售总监、企业发展部总监,也是该公司最早的雇员之一;也曾在诺华公司从事业务开发的工作。他获得了Williams College的学士学位、工商管理硕士学位,并在Kellogg Graduate School of Management以优异成绩获得了医院管理硕士学位,他现任该校生物技术咨询委员会成员。他也是新泽西的生物技术行业贸易集团BioNJ的董事。
Spiro Rombotis has served as a director of the Company since March 2006. He joined Cyclacel as its first Chief Executive Officer in 1997. With over 34 years of experience at three publicly-held biotechs and two pharmas, he participated in several drug programs that reached the market, mainly in inflammation and hematology/oncology. Previously a Vice President and Managing Director, Europe at Liposome subsequently acquired by Elan and a Vice President at Bristol-Myers Squibb, he began his career in the early '80s after training at Novartis as one of the first employees of Centocor a pioneering biopharmaceutical company subsequently acquired by Johnson & Johnson. He holds a BA from Williams College and an MBA and Master's degree in Hospital & Health Services Management with honors from the Kellogg Graduate School of Management at Northwestern University. He also serves on the Board of Trustees of BioNJ, the biotechnology industry trade group in New Jersey.
Paul McBarron

Paul McBarron,2002年1月加入Cyclacel,有着超过24年的制药与生物技术公司工作经验。他曾在Sterling Drug、Sanofi-Winthrop 和SmithKline Beecham 担任财务性的主管工作;1996-2002,他是Shire Pharmaceuticals财务团队的高级成员,曾担任企业财务总监、部门财务总监。他加入Shire之时,该公司是一个新兴的上市公司。他曾是安永会计师事务的合格的特许会计师,还曾任职于苏格兰政府的生命科学产业咨询委员会。


Paul McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001 as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and serves on the Scottish Lifesciences Association Board.
Paul McBarron,2002年1月加入Cyclacel,有着超过24年的制药与生物技术公司工作经验。他曾在Sterling Drug、Sanofi-Winthrop 和SmithKline Beecham 担任财务性的主管工作;1996-2002,他是Shire Pharmaceuticals财务团队的高级成员,曾担任企业财务总监、部门财务总监。他加入Shire之时,该公司是一个新兴的上市公司。他曾是安永会计师事务的合格的特许会计师,还曾任职于苏格兰政府的生命科学产业咨询委员会。
Paul McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001 as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and serves on the Scottish Lifesciences Association Board.
John Banham

John Banham,自1999年以来担任公司的非执行董事,2007年1月以来担任薪酬委员会主席,从1987年到1992年,约翰爵士是英国工业联合会总干事,从1992年到1998年担任国家权力和国家西敏寺银行董事,从1994年到2000年,担任Tarmac PLC的董事,从1995年到2001年,Kingfisher PLC的董事。从2000年到2005年担任 Whitbread PLC董事。从2002年到2005年, Geest plc主席。从2005年到2008年,Spacelabs Healthcare公司的主席。从2006年到2011年,他是庄信万丰公司的主席。他目前是苏尔坦科学有限公司和英国的未来房屋委员会的主席和一个Cyclacel制药公司的独立董事。约翰爵士是一个剑桥大学的毕业生,已经被四个主要英国大学授予荣誉博士学位。


John Banham has served as a director of the Company since March 2006. Sir John Banham currently serves as Chairman of Innoveas International Limited, following a merger of Innoveas ag and Sultan Scientific Limited, where he was Chairman. From January 2000 to May 2014 he served as the senior non-executive director of Invesco Limited. He previously served as Director General of the Confederation of British Industry CBI and has previously held Chairman positions at Johnson Matthey plc, Whitbread plc, Geest plc, ECI Partners LLP, Tarmac plc and Kingfisher plc, and is a former director of Spacelabs Healthcare Inc. His public sector appointments comprise first Controller of the Audit Commission and first Chairman of the Local Government Commission for England. He was formerly Honorary Treasurer of the United Kingdom's Cancer Research Campaign prior to its merger with Imperial Cancer Research. He is a graduate of Cambridge University in Natural Sciences and has honorary degrees from a number of British universities.
John Banham,自1999年以来担任公司的非执行董事,2007年1月以来担任薪酬委员会主席,从1987年到1992年,约翰爵士是英国工业联合会总干事,从1992年到1998年担任国家权力和国家西敏寺银行董事,从1994年到2000年,担任Tarmac PLC的董事,从1995年到2001年,Kingfisher PLC的董事。从2000年到2005年担任 Whitbread PLC董事。从2002年到2005年, Geest plc主席。从2005年到2008年,Spacelabs Healthcare公司的主席。从2006年到2011年,他是庄信万丰公司的主席。他目前是苏尔坦科学有限公司和英国的未来房屋委员会的主席和一个Cyclacel制药公司的独立董事。约翰爵士是一个剑桥大学的毕业生,已经被四个主要英国大学授予荣誉博士学位。
John Banham has served as a director of the Company since March 2006. Sir John Banham currently serves as Chairman of Innoveas International Limited, following a merger of Innoveas ag and Sultan Scientific Limited, where he was Chairman. From January 2000 to May 2014 he served as the senior non-executive director of Invesco Limited. He previously served as Director General of the Confederation of British Industry CBI and has previously held Chairman positions at Johnson Matthey plc, Whitbread plc, Geest plc, ECI Partners LLP, Tarmac plc and Kingfisher plc, and is a former director of Spacelabs Healthcare Inc. His public sector appointments comprise first Controller of the Audit Commission and first Chairman of the Local Government Commission for England. He was formerly Honorary Treasurer of the United Kingdom's Cancer Research Campaign prior to its merger with Imperial Cancer Research. He is a graduate of Cambridge University in Natural Sciences and has honorary degrees from a number of British universities.
David U’Prichard

David U’Prichard,2004年5月加入Cyclacel的董事会。他现任 Druid Consulting的总裁,这是一个制药和生物技术咨询公司,为美国和欧洲的生命科学公司客户提供定制服务;他也是 Druid BioVentures LLP的创始合伙人。他还是BioMotiv的兼职首席科学家、董事,这是Harrington Discovery and Development Project Cleveland的营利性分公司,该机构是受物理学家和科学家启发而设立的全国性加快新药开发的组织。此前,1999-2003,他是3-Dimensional Pharmaceuticals的首席执行官。此外,他在制药和生物技术行业担任过多个职务,包括:SmithKline Beecham Pharmaceuticals研发部的总裁、董事长;Zeneca Pharmaceuticals的执行副总裁、国际研究中心主任、管理委员会成员;ICI Pharmaceuticals的研究部总经理、生物医学研究副总裁; Nova Pharmaceutical Corporation的高级副总裁、科学总监。他现为Life Technologies 和 Iroko Pharmaceuticals 的董事,并曾担任Alpharma、Guilford Pharmaceuticals、Lynx Therapeutics、Naurex 、Silence Therapeutics的董事,以及Oxagen Ltd的非执行董事长。2005-2010,他是私募股权投资机构Red Abbey Venture Partners的投资合伙人;2004-2005,他是宾夕法尼亚州生物科技协会主席;1992-1997,他是Biotechnology Industry Organization (BIO)的董事。1970年,他获得了格拉斯哥大学的药理学学士学位;1975年,他在堪萨斯大学获得药理学博士学位。


David U'Prichard, Ph.D. Dr. U'Prichard joined the Board of Directors of Cyclacel in May 2004. He is currently President of Druid Consulting LLC, a pharmaceutical and biotechnology-consulting firm, providing customized services to life sciences clients in the United States and Europe, and a founding partner of Druid BioVentures LLP. Dr. U'Prichard is also part-time Chief Scientific Officer and board member of BioMotiv, LLC which is the for profit operating company arm of The Harrington Discovery and Development Project Cleveland, OH, a national initiative to accelerate new drug development inspired by physician-scientists. Previously, he was Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc. from 1999 to 2003. In addition, he held a variety of positions within the pharmaceutical and biotechnology industries, including, President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals; Executive Vice President and International Research Director, and a Member of the Board of Management of Zeneca Pharmaceuticals; General Manager, Research Department, ICI Pharmaceuticals, and Vice President Biomedical Research, ICI Pharmaceuticals; and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation. He is currently a director of Life Technologies, Inc. and Iroko Pharmaceuticals and he served as a director of Alpharma, Inc., Guilford Pharmaceuticals Inc., Lynx Therapeutics, Inc., Naurex Inc., Silence Therapeutics plc, and non-executive Chairman of Oxagen Ltd. He was a Venture Partner with Red Abbey Venture Partners, private equity providers, from 2005-2010 Dr. U'Prichard was Chairman of the Pennsylvania Biotechnology Association in 2004-2005 and from 1992 to 1997 he was a member of the board of directors of the Biotechnology Industry Organization (BIO). He received a B.Sc. in Pharmacology from University of Glasgow in 1970 and a Ph.D. in Pharmacology from University of Kansas in 1975.
David U’Prichard,2004年5月加入Cyclacel的董事会。他现任 Druid Consulting的总裁,这是一个制药和生物技术咨询公司,为美国和欧洲的生命科学公司客户提供定制服务;他也是 Druid BioVentures LLP的创始合伙人。他还是BioMotiv的兼职首席科学家、董事,这是Harrington Discovery and Development Project Cleveland的营利性分公司,该机构是受物理学家和科学家启发而设立的全国性加快新药开发的组织。此前,1999-2003,他是3-Dimensional Pharmaceuticals的首席执行官。此外,他在制药和生物技术行业担任过多个职务,包括:SmithKline Beecham Pharmaceuticals研发部的总裁、董事长;Zeneca Pharmaceuticals的执行副总裁、国际研究中心主任、管理委员会成员;ICI Pharmaceuticals的研究部总经理、生物医学研究副总裁; Nova Pharmaceutical Corporation的高级副总裁、科学总监。他现为Life Technologies 和 Iroko Pharmaceuticals 的董事,并曾担任Alpharma、Guilford Pharmaceuticals、Lynx Therapeutics、Naurex 、Silence Therapeutics的董事,以及Oxagen Ltd的非执行董事长。2005-2010,他是私募股权投资机构Red Abbey Venture Partners的投资合伙人;2004-2005,他是宾夕法尼亚州生物科技协会主席;1992-1997,他是Biotechnology Industry Organization (BIO)的董事。1970年,他获得了格拉斯哥大学的药理学学士学位;1975年,他在堪萨斯大学获得药理学博士学位。
David U'Prichard, Ph.D. Dr. U'Prichard joined the Board of Directors of Cyclacel in May 2004. He is currently President of Druid Consulting LLC, a pharmaceutical and biotechnology-consulting firm, providing customized services to life sciences clients in the United States and Europe, and a founding partner of Druid BioVentures LLP. Dr. U'Prichard is also part-time Chief Scientific Officer and board member of BioMotiv, LLC which is the for profit operating company arm of The Harrington Discovery and Development Project Cleveland, OH, a national initiative to accelerate new drug development inspired by physician-scientists. Previously, he was Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc. from 1999 to 2003. In addition, he held a variety of positions within the pharmaceutical and biotechnology industries, including, President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals; Executive Vice President and International Research Director, and a Member of the Board of Management of Zeneca Pharmaceuticals; General Manager, Research Department, ICI Pharmaceuticals, and Vice President Biomedical Research, ICI Pharmaceuticals; and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation. He is currently a director of Life Technologies, Inc. and Iroko Pharmaceuticals and he served as a director of Alpharma, Inc., Guilford Pharmaceuticals Inc., Lynx Therapeutics, Inc., Naurex Inc., Silence Therapeutics plc, and non-executive Chairman of Oxagen Ltd. He was a Venture Partner with Red Abbey Venture Partners, private equity providers, from 2005-2010 Dr. U'Prichard was Chairman of the Pennsylvania Biotechnology Association in 2004-2005 and from 1992 to 1997 he was a member of the board of directors of the Biotechnology Industry Organization (BIO). He received a B.Sc. in Pharmacology from University of Glasgow in 1970 and a Ph.D. in Pharmacology from University of Kansas in 1975.
Lloyd Sems

Lloyd Sems,Sems Capital 和 Capital Edge的总裁,他在2003年创办上述两个公司。之前,他曾担任Watchpoint Asset Management的研究总监、组合投资经理。他获得了Albright College的工商管理与财务学士学位。2010年2月至2010年4月,他任职于EMAK Worldwide(EMAK)的董事会;2009年4月至2012年12月,担任Sport-Haley Holdings (SPOR)的董事。目前,他是Selectica(SLTC)的董事,他于2008年6月加入该公司。


Lloyd Sems has served as a director of the Company and on behalf of the holders of the Preferred Stock since May 2011. Mr. Sems currently serves as President of Sems Capital, LLC and Capital Edge, LLC, both of which he founded in October 2003. Previously, Mr. Sems served as Director of Research and Portfolio Manager for Watchpoint Asset Management. Mr. Sems served on the boards of EMAK Worldwide, Inc. from February 2010 to April 2010 Sport-Haley Holdings from April 2009 to December 2012 and Determine, Inc. from June 2008 until its sale in 2019. Mr. Sems holds a Bachelor of Science degree in Business Administration and Finance from Albright College.
Lloyd Sems,Sems Capital 和 Capital Edge的总裁,他在2003年创办上述两个公司。之前,他曾担任Watchpoint Asset Management的研究总监、组合投资经理。他获得了Albright College的工商管理与财务学士学位。2010年2月至2010年4月,他任职于EMAK Worldwide(EMAK)的董事会;2009年4月至2012年12月,担任Sport-Haley Holdings (SPOR)的董事。目前,他是Selectica(SLTC)的董事,他于2008年6月加入该公司。
Lloyd Sems has served as a director of the Company and on behalf of the holders of the Preferred Stock since May 2011. Mr. Sems currently serves as President of Sems Capital, LLC and Capital Edge, LLC, both of which he founded in October 2003. Previously, Mr. Sems served as Director of Research and Portfolio Manager for Watchpoint Asset Management. Mr. Sems served on the boards of EMAK Worldwide, Inc. from February 2010 to April 2010 Sport-Haley Holdings from April 2009 to December 2012 and Determine, Inc. from June 2008 until its sale in 2019. Mr. Sems holds a Bachelor of Science degree in Business Administration and Finance from Albright College.
Gregory T. Hradsky

Gregory T. Hradsky,2011年5月起代表股东Preferred Stock出任本公司董事会。2006年2月以来,他是一名独立的财务顾问。自2008年6月起,他是Costar Technologies的董事,现任其审核委员会主席。2003年5月和2006年2月之间,他担任全球性的投资公司 Avenue Capital Group的副总裁,管理不良证券投资组合、重组后股票及其它投资。1999-2003,他创办了 Bellport Capital,也是该公司管理合伙人,这是专注于不良证券的投资公司。此前,1993-1998,他是瑞银证券公司不良证券部门的总经理、负责人。他在1991年加入瑞银,担任不良债务研究分析员。加入瑞银之前,1988-1991,他是第一波士顿公司不良证券部门和高收益研究部门的成员。1983年,他在T. Rowe Price Associates开始职业生涯,1986年之前在固定收益部工作。他获得了马里兰州Loyola College的学士学位、宾州大学沃顿商学院的工商管理硕士学位。


Gregory T. Hradsky has served as a director of the Company and on behalf of holders of the Preferred Stock since May 2011. Mr. Hradsky has been an independent financial consultant since February 2006. He has served on the board of directors of Costar Technologies, Inc. since June 2008 where he is Chairman of the Audit Committee. From 2003 to 2006 Mr. Hradsky was a Vice President of Avenue Capital Group, a global investment firm, where he managed a portfolio of distressed securities and other investments. From 1999 until 2003 Mr. Hradsky was the founder and Managing Partner of Bellport Capital, an investment firm specializing in distressed securities. Mr. Hradsky was a Managing Director and Head of the Distressed Securities Group at UBS Securities from 1993 until 1998 and joined UBS in 1991. Prior to UBS, Mr. Hradsky held investment positions at CS First Boston and T. Rowe Price. Mr. Hradsky has a B.A. from Loyola College in Maryland and an M.B.A. from the Wharton School of the University of Pennsylvania.
Gregory T. Hradsky,2011年5月起代表股东Preferred Stock出任本公司董事会。2006年2月以来,他是一名独立的财务顾问。自2008年6月起,他是Costar Technologies的董事,现任其审核委员会主席。2003年5月和2006年2月之间,他担任全球性的投资公司 Avenue Capital Group的副总裁,管理不良证券投资组合、重组后股票及其它投资。1999-2003,他创办了 Bellport Capital,也是该公司管理合伙人,这是专注于不良证券的投资公司。此前,1993-1998,他是瑞银证券公司不良证券部门的总经理、负责人。他在1991年加入瑞银,担任不良债务研究分析员。加入瑞银之前,1988-1991,他是第一波士顿公司不良证券部门和高收益研究部门的成员。1983年,他在T. Rowe Price Associates开始职业生涯,1986年之前在固定收益部工作。他获得了马里兰州Loyola College的学士学位、宾州大学沃顿商学院的工商管理硕士学位。
Gregory T. Hradsky has served as a director of the Company and on behalf of holders of the Preferred Stock since May 2011. Mr. Hradsky has been an independent financial consultant since February 2006. He has served on the board of directors of Costar Technologies, Inc. since June 2008 where he is Chairman of the Audit Committee. From 2003 to 2006 Mr. Hradsky was a Vice President of Avenue Capital Group, a global investment firm, where he managed a portfolio of distressed securities and other investments. From 1999 until 2003 Mr. Hradsky was the founder and Managing Partner of Bellport Capital, an investment firm specializing in distressed securities. Mr. Hradsky was a Managing Director and Head of the Distressed Securities Group at UBS Securities from 1993 until 1998 and joined UBS in 1991. Prior to UBS, Mr. Hradsky held investment positions at CS First Boston and T. Rowe Price. Mr. Hradsky has a B.A. from Loyola College in Maryland and an M.B.A. from the Wharton School of the University of Pennsylvania.
Samuel L. Barker

Samuel L. Barker,博士;自2000年3月以来担任董事,从2005年到2012年担任董事会主席。2001年,他共同创立 Clearview Projects公司——为生物制药公司提供合作和交易服务的提供者,并从2003年到2004年担任总裁兼首席执行官。他在百时美施贵宝公司(Bristol-Myers Squibb Company)担任过一系列的领导职务,直到1999年退休。他在百时美施贵宝的职务包括在1998年任全球特许经营管理和战略在执行副总裁,从1992年到1997年任美国药品总裁,从1990年到1992年任百时美施贵宝洲际商业运作总裁。1990年之前,他在美施贵宝制药担任研发、制造、财务、业务开发及销售和营销的高管职位。他目前从2006年到2009年担任 Cadence Pharmaceuticals有限公司和AtheroGenics有限公司的董事。他持有亨德森州立大学(Henderson State College)学士学位,阿肯色大学(University of Arkansas)硕士学位,以及普渡大学(Purdue University)的博士学位。


Samuel L. Barker has been a director since March 2000 and served as chairman of our board of directors from 2005 to 2012. Dr. Barker previously co-founded and served as president and chief executive officer of Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as executive vice president, Worldwide Franchise Management and Strategy; president, United States Pharmaceuticals; and president, Bristol-Myers Squibb Intercontinental Commercial Operations. Dr. Barker also previously held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals. Dr. Barker currently serves as a director of Cyclacel Pharmaceuticals, Inc. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.
Samuel L. Barker,博士;自2000年3月以来担任董事,从2005年到2012年担任董事会主席。2001年,他共同创立 Clearview Projects公司——为生物制药公司提供合作和交易服务的提供者,并从2003年到2004年担任总裁兼首席执行官。他在百时美施贵宝公司(Bristol-Myers Squibb Company)担任过一系列的领导职务,直到1999年退休。他在百时美施贵宝的职务包括在1998年任全球特许经营管理和战略在执行副总裁,从1992年到1997年任美国药品总裁,从1990年到1992年任百时美施贵宝洲际商业运作总裁。1990年之前,他在美施贵宝制药担任研发、制造、财务、业务开发及销售和营销的高管职位。他目前从2006年到2009年担任 Cadence Pharmaceuticals有限公司和AtheroGenics有限公司的董事。他持有亨德森州立大学(Henderson State College)学士学位,阿肯色大学(University of Arkansas)硕士学位,以及普渡大学(Purdue University)的博士学位。
Samuel L. Barker has been a director since March 2000 and served as chairman of our board of directors from 2005 to 2012. Dr. Barker previously co-founded and served as president and chief executive officer of Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as executive vice president, Worldwide Franchise Management and Strategy; president, United States Pharmaceuticals; and president, Bristol-Myers Squibb Intercontinental Commercial Operations. Dr. Barker also previously held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals. Dr. Barker currently serves as a director of Cyclacel Pharmaceuticals, Inc. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.
Christopher S. Henney

Christopher S. Henney,他是哲学博士。他担任我们的董事会主席(自2006年9月以来),以及我们董事会的成员(2005年3月以来)。他是我们薪酬和公司治理和提名委员会的成员。他曾担任 Dendreon Corporation(他共同创立的上市的生物技术公司)的董事长兼首席执行官(从1995年到2003年),以及执行主席(从2003年到2005年)。他也是Immunex Corporation和ICOS Corporation(两家公司都是上市生物技术公司)的共同创始人。我们公司治理和提名委员会肯定了他有资格担任董事会成员,包括他担任Dendreon公司、Immunex公司和ICOS公司的共同创办人,以及几个发展阶段生物技术公司的董事会成员。通过任职生物技术公司,担任从创始人到商业化产品的候选人职务,他获得经验,从而为我们的董事会提供了战略、运营和临床发展方面的重要见解。他目前担任Cyclacel Pharmaceuticals公司(一个发展阶段生物制药公司)的副董事会主席、Anthera Pharmaceuticals公司(生物制药公司)的董事会主席,以及Prothena Corporation公司(生物制药公司)的董事会成员。他曾担任SGX Pharmaceuticals公司(生物制药公司,于2008年被 Eli Lilly 公司收购)的主席,以及AVI BioPharma公司(生物制药公司)(直到2010年6月)和Mymetics 公司(2011年)的董事会成员。他持有英国伯明翰大学(the University of Birmingham, England,)实验病理学博士学位,以及免疫学领域的科学博士学位。基于他对母校的生物技术产业的贡献,他于2011年获得了大学的荣誉博士学位。他是Johns Hopkins University、the University of Washington 和the Fred Hutchinson Cancer Research Center的前任免疫学和微生物学教授,并担任教师职位。


Christopher S. Henney, is Vice-Chairman of the Board of Cyclacel Pharmaceuticals, Inc. From 1995 to 2004 he served as Chairman of the Board and Chief Executive Officer of Dendreon Corporation, a biotechnology company that he co-founded. Dr. Henney also co-founded and served as a director and in executive positions at Immunex Corporation and ICOS Corporation both biotechnology companies. He was Chairman of the Board of Cascadian Therapeutics, Inc. (a biotechnology company) from 2006 to 2018 where he also served as interim President and Chief Executive Officer for part of 2016 and served as Chairman of the Board of Anthera Pharmaceuticals, Inc. (a biopharmaceutical company) from 2008 to 2018. Dr. Henney is a 2011 inductee to The Biotechnology Hall of Fame. He earned his B.Sc. in medical biochemistry, his Ph.D. in experimental pathology and his D.Sc. for contributions to the field of immunology from the University of Birmingham, England. Dr. Henney has served on our Board since 2013.
Christopher S. Henney,他是哲学博士。他担任我们的董事会主席(自2006年9月以来),以及我们董事会的成员(2005年3月以来)。他是我们薪酬和公司治理和提名委员会的成员。他曾担任 Dendreon Corporation(他共同创立的上市的生物技术公司)的董事长兼首席执行官(从1995年到2003年),以及执行主席(从2003年到2005年)。他也是Immunex Corporation和ICOS Corporation(两家公司都是上市生物技术公司)的共同创始人。我们公司治理和提名委员会肯定了他有资格担任董事会成员,包括他担任Dendreon公司、Immunex公司和ICOS公司的共同创办人,以及几个发展阶段生物技术公司的董事会成员。通过任职生物技术公司,担任从创始人到商业化产品的候选人职务,他获得经验,从而为我们的董事会提供了战略、运营和临床发展方面的重要见解。他目前担任Cyclacel Pharmaceuticals公司(一个发展阶段生物制药公司)的副董事会主席、Anthera Pharmaceuticals公司(生物制药公司)的董事会主席,以及Prothena Corporation公司(生物制药公司)的董事会成员。他曾担任SGX Pharmaceuticals公司(生物制药公司,于2008年被 Eli Lilly 公司收购)的主席,以及AVI BioPharma公司(生物制药公司)(直到2010年6月)和Mymetics 公司(2011年)的董事会成员。他持有英国伯明翰大学(the University of Birmingham, England,)实验病理学博士学位,以及免疫学领域的科学博士学位。基于他对母校的生物技术产业的贡献,他于2011年获得了大学的荣誉博士学位。他是Johns Hopkins University、the University of Washington 和the Fred Hutchinson Cancer Research Center的前任免疫学和微生物学教授,并担任教师职位。
Christopher S. Henney, is Vice-Chairman of the Board of Cyclacel Pharmaceuticals, Inc. From 1995 to 2004 he served as Chairman of the Board and Chief Executive Officer of Dendreon Corporation, a biotechnology company that he co-founded. Dr. Henney also co-founded and served as a director and in executive positions at Immunex Corporation and ICOS Corporation both biotechnology companies. He was Chairman of the Board of Cascadian Therapeutics, Inc. (a biotechnology company) from 2006 to 2018 where he also served as interim President and Chief Executive Officer for part of 2016 and served as Chairman of the Board of Anthera Pharmaceuticals, Inc. (a biopharmaceutical company) from 2008 to 2018. Dr. Henney is a 2011 inductee to The Biotechnology Hall of Fame. He earned his B.Sc. in medical biochemistry, his Ph.D. in experimental pathology and his D.Sc. for contributions to the field of immunology from the University of Birmingham, England. Dr. Henney has served on our Board since 2013.
David U'Prichard

David U'Prichard是一名博士兼董事。自2012年9月起,David U'Prichard博士一直担任Cyclacel Pharmaceuticals, Inc.董事会成员。自2004年5月起,U'Prichard董事还任职Cyclacel Pharmaceuticals, Inc.的董事会,担任Life Technologies, Inc.的主席。2010年加入Iroko Pharmaceuticals的董事会。自2003年以来,他一直担任Druid Consulting LLC(一家制药和生物技术咨询公司,提供美国和欧洲生命科学客户的定制服务)的总裁。自2009年起,担任Druid Bio Ventures LLP的创始合伙人。 U'Prichard博士也是BioMotiv的兼职首席科学官,一家Harrington探索与发展项目克利夫兰的运营公司和OH(一家由医师科学家创立的国内首创加快新药开发);自2012年以来,一直担任此职。此前,1999年至2003年他是3-Dimensional Pharmaceuticals, Inc.的首席执行官。 此外,他在制药和生物技术产业担任过各种职务,包括1997年至1999年担任SmithKline Beecham Pharmaceuticals研发的总裁和主席;1994至1997年,担任执行副总裁兼国际研究总监和Zeneca Pharmaceuticals管理的董事会成员;1991年至1994年,担任研究部和ICI Pharmaceuticals的总经理;1986年至1991年,担任ICI Pharmaceuticals生物医学研究的副总裁;1983年至1986年,是Nova Pharmaceutical Corporation的高级副总裁兼科学总监。2007至2008年,他是Alpharma Inc.的董事;2003年至2005年,担任Guilford Pharmaceuticals Inc.的董事;2004年至2011年,担任Silence Therapeutics plc的董事。2001年至2006年,担任Lynx Therapeutics, Inc.的董事;2004年至2011年,担任Oxagen Ltd.的非执行主席。2005年至2010年,他是Red Abbey Venture Partners(一家私募股权投资机构的提供商)的风险合伙人。2004年至2005年,U'Prichard博士是宾夕法尼亚州生物技术协会主席;1992年至1997年,他是生物技术工业组织(BIO)的董事会成员。他于1975年获得The University of Glasgow药理学的心理学士学位,The University of Kansas的药理学的博士学位。


David U'Prichard, PhD, Director: Dr. David U'Prichard has served as a member of Cyclacel Pharmaceuticals, Inc. board of directors since September 2012. Dr. U'Prichard has also served on the boards of directors of Cyclacel Pharmaceuticals, Inc., as Chairman, and Life Technologies, Inc. since May 2004 and joined the board of Iroko Pharmaceuticals in 2010. He has been President of Druid Consulting LLC, a pharmaceutical and biotechnology-consulting firm, providing customized services to life sciences clients in the United States and Europe, since 2003 and a founding partner of Druid Bio Ventures LLP since 2009. Dr. U'Prichard is also part-time Chief Scientific Officer of BioMotiv, the operating company arm of The Harrington Discovery and Development Project Cleveland, OH, a national initiative to accelerate new drug development inspired by physician-scientists, where he has served since 2012. Previously, he was Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc. from 1999 to 2003. In addition, he held a variety of positions within the pharmaceutical and biotechnology industries, including, President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals from 1997 to 1999; Executive Vice President and International Research Director, and a Member of the Board of Management of Zeneca Pharmaceuticals from 1994 to 1997; General Manger, Research Department, ICI Pharmaceuticals, from 1991 to 1994 and Vice President Biomedical Research, ICI Pharmaceuticals, from 1986 to 1991; and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation from 1983 to 1986. He was a director of Alpharma Inc. from 2007 to 2008 Guilford Pharmaceuticals Inc. from 2003 to 2005 Silence Therapeutics plc from 2004 to 2011 Lynx Therapeutics, Inc. from 2001 to 2006 and non-executive Chairman of Oxagen Ltd. from 2004 to 2011. He was a Venture Partner with Red Abbey Venture Partners, private equity providers, from 2005 to 2010. Dr. U'Prichard was Chairman of the Pennsylvania Biotechnology Association from 2004 to 2005 and from 1992 to 1997 he was a member of the board of directors of the Biotechnology Industry Organization (BIO). He received a BSc in Pharmacology from The University of Glasgow and a PhD in Pharmacology from The University of Kansas in 1975.
David U'Prichard是一名博士兼董事。自2012年9月起,David U'Prichard博士一直担任Cyclacel Pharmaceuticals, Inc.董事会成员。自2004年5月起,U'Prichard董事还任职Cyclacel Pharmaceuticals, Inc.的董事会,担任Life Technologies, Inc.的主席。2010年加入Iroko Pharmaceuticals的董事会。自2003年以来,他一直担任Druid Consulting LLC(一家制药和生物技术咨询公司,提供美国和欧洲生命科学客户的定制服务)的总裁。自2009年起,担任Druid Bio Ventures LLP的创始合伙人。 U'Prichard博士也是BioMotiv的兼职首席科学官,一家Harrington探索与发展项目克利夫兰的运营公司和OH(一家由医师科学家创立的国内首创加快新药开发);自2012年以来,一直担任此职。此前,1999年至2003年他是3-Dimensional Pharmaceuticals, Inc.的首席执行官。 此外,他在制药和生物技术产业担任过各种职务,包括1997年至1999年担任SmithKline Beecham Pharmaceuticals研发的总裁和主席;1994至1997年,担任执行副总裁兼国际研究总监和Zeneca Pharmaceuticals管理的董事会成员;1991年至1994年,担任研究部和ICI Pharmaceuticals的总经理;1986年至1991年,担任ICI Pharmaceuticals生物医学研究的副总裁;1983年至1986年,是Nova Pharmaceutical Corporation的高级副总裁兼科学总监。2007至2008年,他是Alpharma Inc.的董事;2003年至2005年,担任Guilford Pharmaceuticals Inc.的董事;2004年至2011年,担任Silence Therapeutics plc的董事。2001年至2006年,担任Lynx Therapeutics, Inc.的董事;2004年至2011年,担任Oxagen Ltd.的非执行主席。2005年至2010年,他是Red Abbey Venture Partners(一家私募股权投资机构的提供商)的风险合伙人。2004年至2005年,U'Prichard博士是宾夕法尼亚州生物技术协会主席;1992年至1997年,他是生物技术工业组织(BIO)的董事会成员。他于1975年获得The University of Glasgow药理学的心理学士学位,The University of Kansas的药理学的博士学位。
David U'Prichard, PhD, Director: Dr. David U'Prichard has served as a member of Cyclacel Pharmaceuticals, Inc. board of directors since September 2012. Dr. U'Prichard has also served on the boards of directors of Cyclacel Pharmaceuticals, Inc., as Chairman, and Life Technologies, Inc. since May 2004 and joined the board of Iroko Pharmaceuticals in 2010. He has been President of Druid Consulting LLC, a pharmaceutical and biotechnology-consulting firm, providing customized services to life sciences clients in the United States and Europe, since 2003 and a founding partner of Druid Bio Ventures LLP since 2009. Dr. U'Prichard is also part-time Chief Scientific Officer of BioMotiv, the operating company arm of The Harrington Discovery and Development Project Cleveland, OH, a national initiative to accelerate new drug development inspired by physician-scientists, where he has served since 2012. Previously, he was Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc. from 1999 to 2003. In addition, he held a variety of positions within the pharmaceutical and biotechnology industries, including, President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals from 1997 to 1999; Executive Vice President and International Research Director, and a Member of the Board of Management of Zeneca Pharmaceuticals from 1994 to 1997; General Manger, Research Department, ICI Pharmaceuticals, from 1991 to 1994 and Vice President Biomedical Research, ICI Pharmaceuticals, from 1986 to 1991; and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation from 1983 to 1986. He was a director of Alpharma Inc. from 2007 to 2008 Guilford Pharmaceuticals Inc. from 2003 to 2005 Silence Therapeutics plc from 2004 to 2011 Lynx Therapeutics, Inc. from 2001 to 2006 and non-executive Chairman of Oxagen Ltd. from 2004 to 2011. He was a Venture Partner with Red Abbey Venture Partners, private equity providers, from 2005 to 2010. Dr. U'Prichard was Chairman of the Pennsylvania Biotechnology Association from 2004 to 2005 and from 1992 to 1997 he was a member of the board of directors of the Biotechnology Industry Organization (BIO). He received a BSc in Pharmacology from The University of Glasgow and a PhD in Pharmacology from The University of Kansas in 1975.

高管简历

中英对照 |  中文 |  英文
Spiro Rombotis

Spiro Rombotis,1997年加入Cyclacel,担任第一首席执行官,有着超过30年的制药与生物技术公司工作经验。之前,他曾在Liposome Company担任国际运营与业务开发副总裁、欧洲区总经理、日本合资企业总监。他还曾担任施贵宝的中欧与东欧区制药副总裁、国际营销总监。他曾是Centocor欧洲营销与销售总监、企业发展部总监,也是该公司最早的雇员之一;也曾在诺华公司从事业务开发的工作。他获得了Williams College的学士学位、工商管理硕士学位,并在Kellogg Graduate School of Management以优异成绩获得了医院管理硕士学位,他现任该校生物技术咨询委员会成员。他也是新泽西的生物技术行业贸易集团BioNJ的董事。


Spiro Rombotis has served as a director of the Company since March 2006. He joined Cyclacel as its first Chief Executive Officer in 1997. With over 34 years of experience at three publicly-held biotechs and two pharmas, he participated in several drug programs that reached the market, mainly in inflammation and hematology/oncology. Previously a Vice President and Managing Director, Europe at Liposome subsequently acquired by Elan and a Vice President at Bristol-Myers Squibb, he began his career in the early '80s after training at Novartis as one of the first employees of Centocor a pioneering biopharmaceutical company subsequently acquired by Johnson & Johnson. He holds a BA from Williams College and an MBA and Master's degree in Hospital & Health Services Management with honors from the Kellogg Graduate School of Management at Northwestern University. He also serves on the Board of Trustees of BioNJ, the biotechnology industry trade group in New Jersey.
Spiro Rombotis,1997年加入Cyclacel,担任第一首席执行官,有着超过30年的制药与生物技术公司工作经验。之前,他曾在Liposome Company担任国际运营与业务开发副总裁、欧洲区总经理、日本合资企业总监。他还曾担任施贵宝的中欧与东欧区制药副总裁、国际营销总监。他曾是Centocor欧洲营销与销售总监、企业发展部总监,也是该公司最早的雇员之一;也曾在诺华公司从事业务开发的工作。他获得了Williams College的学士学位、工商管理硕士学位,并在Kellogg Graduate School of Management以优异成绩获得了医院管理硕士学位,他现任该校生物技术咨询委员会成员。他也是新泽西的生物技术行业贸易集团BioNJ的董事。
Spiro Rombotis has served as a director of the Company since March 2006. He joined Cyclacel as its first Chief Executive Officer in 1997. With over 34 years of experience at three publicly-held biotechs and two pharmas, he participated in several drug programs that reached the market, mainly in inflammation and hematology/oncology. Previously a Vice President and Managing Director, Europe at Liposome subsequently acquired by Elan and a Vice President at Bristol-Myers Squibb, he began his career in the early '80s after training at Novartis as one of the first employees of Centocor a pioneering biopharmaceutical company subsequently acquired by Johnson & Johnson. He holds a BA from Williams College and an MBA and Master's degree in Hospital & Health Services Management with honors from the Kellogg Graduate School of Management at Northwestern University. He also serves on the Board of Trustees of BioNJ, the biotechnology industry trade group in New Jersey.
Paul McBarron

Paul McBarron,2002年1月加入Cyclacel,有着超过24年的制药与生物技术公司工作经验。他曾在Sterling Drug、Sanofi-Winthrop 和SmithKline Beecham 担任财务性的主管工作;1996-2002,他是Shire Pharmaceuticals财务团队的高级成员,曾担任企业财务总监、部门财务总监。他加入Shire之时,该公司是一个新兴的上市公司。他曾是安永会计师事务的合格的特许会计师,还曾任职于苏格兰政府的生命科学产业咨询委员会。


Paul McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001 as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and serves on the Scottish Lifesciences Association Board.
Paul McBarron,2002年1月加入Cyclacel,有着超过24年的制药与生物技术公司工作经验。他曾在Sterling Drug、Sanofi-Winthrop 和SmithKline Beecham 担任财务性的主管工作;1996-2002,他是Shire Pharmaceuticals财务团队的高级成员,曾担任企业财务总监、部门财务总监。他加入Shire之时,该公司是一个新兴的上市公司。他曾是安永会计师事务的合格的特许会计师,还曾任职于苏格兰政府的生命科学产业咨询委员会。
Paul McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001 as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and serves on the Scottish Lifesciences Association Board.
Judy Chiao

Judy Chiao,女,2004年12月加入Cyclacel。2001年12月至2004年9月,她在Merck & Co。的全资子公司Aton Pharma工作,最近的职务是肿瘤学临床研发副总裁。在Aton被Merck收购之前,她负责领导ZOLINZAr的临床开发,这是一种针对血液和实体肿瘤适应症的组蛋白去乙酰化酶抑制剂。从2000年7月至2001年12月,她是美国食品药物管理局药品评价和研究中心肿瘤药物产品部的高级医药评审员,她是该机构的多种肿瘤学药物和监管主体的主要评审员。在肿瘤药物咨询委员会中,她还会介绍美国食品药品管理局关于一些新药物应用的评论。她以优异成绩获得了哥伦比亚大学的化学学士学位,在哈佛医学院获得了医学学位。她在纽约的哥伦比亚长老会医学中心完成了内科实习医生和住院医生阶段,并曾担任斯隆凯特林癌症研究所的分子药理学的研究员,以及纪念斯隆-凯特琳癌症中心血液学/肿瘤学的临床研究员,以上两个机构都在纽约。她也一直是许多美国食品药物管理局相关工作组的成员,也是Pharsight-FDA合作研究和开发协议(CRADA)关于用以药物开发的临床试验模拟及群体药代动力学分析软件的核心成员。


Judy Chiao joined Cyclacel in December 2004. From December 2001 to September 2004 she was employed at Aton Pharma, Inc., a wholly owned subsidiary of Merck & Co. Inc., most recently as Vice President, Oncology Clinical Research and Development. Prior to Aton’s acquisition by Merck, she was responsible for leading the clinical development of Zolinza, a histone deacetylase inhibitor, for hematologic and solid tumor indications. From July 2000 to December 2001 Dr. Chiao was a Senior Medical Reviewer, Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, where she was the agency’s primary reviewer for a range of oncology drugs and regulatory subjects. She also presented the FDA’s views in several New Drug Application reviews at Oncology Drug Advisory Committees. Dr. Chiao earned her Bachelor of Science in Chemistry summa cum laude at Columbia University and received her medical degree from Harvard Medical School. Her internship and residency in internal medicine was carried out at Columbia-Presbyterian Medical Center, New York and she held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center, both in New York. She has also been a member of a number of FDA-related working groups and has also been a Core Member of the Pharsight-FDA Cooperative Research and Development Agreement CRADA on clinical trial simulation and population pharmacokinetic analysis software for drug development.
Judy Chiao,女,2004年12月加入Cyclacel。2001年12月至2004年9月,她在Merck & Co。的全资子公司Aton Pharma工作,最近的职务是肿瘤学临床研发副总裁。在Aton被Merck收购之前,她负责领导ZOLINZAr的临床开发,这是一种针对血液和实体肿瘤适应症的组蛋白去乙酰化酶抑制剂。从2000年7月至2001年12月,她是美国食品药物管理局药品评价和研究中心肿瘤药物产品部的高级医药评审员,她是该机构的多种肿瘤学药物和监管主体的主要评审员。在肿瘤药物咨询委员会中,她还会介绍美国食品药品管理局关于一些新药物应用的评论。她以优异成绩获得了哥伦比亚大学的化学学士学位,在哈佛医学院获得了医学学位。她在纽约的哥伦比亚长老会医学中心完成了内科实习医生和住院医生阶段,并曾担任斯隆凯特林癌症研究所的分子药理学的研究员,以及纪念斯隆-凯特琳癌症中心血液学/肿瘤学的临床研究员,以上两个机构都在纽约。她也一直是许多美国食品药物管理局相关工作组的成员,也是Pharsight-FDA合作研究和开发协议(CRADA)关于用以药物开发的临床试验模拟及群体药代动力学分析软件的核心成员。
Judy Chiao joined Cyclacel in December 2004. From December 2001 to September 2004 she was employed at Aton Pharma, Inc., a wholly owned subsidiary of Merck & Co. Inc., most recently as Vice President, Oncology Clinical Research and Development. Prior to Aton’s acquisition by Merck, she was responsible for leading the clinical development of Zolinza, a histone deacetylase inhibitor, for hematologic and solid tumor indications. From July 2000 to December 2001 Dr. Chiao was a Senior Medical Reviewer, Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, where she was the agency’s primary reviewer for a range of oncology drugs and regulatory subjects. She also presented the FDA’s views in several New Drug Application reviews at Oncology Drug Advisory Committees. Dr. Chiao earned her Bachelor of Science in Chemistry summa cum laude at Columbia University and received her medical degree from Harvard Medical School. Her internship and residency in internal medicine was carried out at Columbia-Presbyterian Medical Center, New York and she held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center, both in New York. She has also been a member of a number of FDA-related working groups and has also been a Core Member of the Pharsight-FDA Cooperative Research and Development Agreement CRADA on clinical trial simulation and population pharmacokinetic analysis software for drug development.